What sector is PTNT in?

Healthcare, in the Pharmaceuticals industry.

Cboe BZX · PTNTHealthcarePharmaceuticals

Corgi IP Licensing & Royalties ETF (PTNT)

$24.99−1.08%

Close Nov 12, 2026 · split-adjusted

Nov 12, 2026$25.08▲ 2.55% in range

Sep 11, 2026Low $23.83 · High $25.27Nov 12, 2026

What changed · written from our data

As of Nov 12, 2026

Corgi IP Licensing & Royalties ETF closed at $24.99 on Nov 12, down 1.08%, 1.1% below its highest close since Sep 11. Volume of 113 shares was 1.19× its 20-day average (close to normal).

Split-adjusted performance: +4.1% over one month.

In the quarter ended Jun 30, 2026, revenue was $300.77K, with a net margin of -1449.1%.

Short interest was 17 shares at the Oct 30 settlement, down 73.8% from the prior report (1.0 days to cover).

Market cap—

Revenue · quarter$300.8K—

Diluted EPS$-1.16—

P/E · TTM—

Net margin-1,449.1%Gross 100.0%

Dividend yieldNone

Range since Sep 1123.83 – 25.27−1.1% from high

Volume1131.19× 20-day avg

Volatility · 60d—Annualised

Short % of float—1.0 days to cover

Net cash$7.5MCash $7.5M

Next earnings—Not scheduled

Split-adjusted performance

1W +2.9%1M +4.1%3M —6M —YTD —1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 417 companies (100 = best)

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size—

Industry medians: 6-month return −26.3%, revenue growth +9.3%, net margin −35.1%, P/E 16.5×.

Short interest

Details →

Shares short17−73.8% vs prior

Days to cover1.0Settled Oct 30

% of float—

Short vol. 10d32.4%of daily volume

News about Corgi IP Licensing & Royalties ETF

All news →

No recent articles focused on Corgi IP Licensing & Royalties ETF.

Quick answers

What sector is PTNT in?: Healthcare, in the Pharmaceuticals industry.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology